Filter

581 - 590 of 781 Results

  • The Development of Direct-to-Consumer Prescription Drug Advertising Regulation

    Other Post

    This article, which appears in the Food and Drug Law Journal, vol. 57, no. 3, 2002, pp. 423-444 was based on a report written by F.B. Palumbo and C.D. Mullins at the University of Maryland School of Pharmacy Center on Drugs and Public Policy and funded by the Kaiser Family Foundation.

  • Medicare Part D: A First Look at Part D Plan Offerings in 2013

    Report

    This data spotlight examines the stand-alone Part D drug plan options available to Medicare beneficiaries in 2013 during the open enrollment period, which runs from October 15 to December 7, 2012. The analysis is the first in a series of planned reports examining the private plan choices available to Medicare beneficiaries for 2013.

  • Medicare and Prescription Drugs, Fact Sheet

    Fact Sheet

    This fact sheet, updated in April 2003, profiles current sources of prescription drug coverage among the Medicare population, describes the characteristics of beneficiaries who lack drug coverage and the implications of being without such coverage, and provides current data on prescription drug use and spending. Fact Sheet (.

  • Federal Policies Affecting The Cost and Availability of New Pharmaceuticals

    Report

    This report by Michael Gluck of the Georgetown University Institute for Health Care Research and Policy examines several ways in which the federal government influences the availability and cost of prescription drugs, including 1) intellectual property protection the laws and policies which regulate and influence patents and generic competition (include the Hatch-Waxman Act), 2) federal…

  • Medicare Part D 2010 Data Spotlight: Premiums

    Report

    Medicare Part D helps cover the cost of outpatient prescription drugs for 27 million beneficiaries enrolled in private stand-alone prescription drug plans (PDPs) and Medicare Advantage prescription drug (MA-PD) plans. The majority of Part D enrollees pay a monthly premium for Medicare drug coverage.

  • Medicare Part D 2010 Data Spotlight: The Coverage Gap

    Report

    This data spotlight examines the coverage gap, or "doughnut hole," in Medicare stand-alone drug plans available in 2010. While in the gap in coverage, Part D enrollees (other than those receiving low-income subsidies) are required to pay 100 percent of total drug costs until they reach the catastrophic coverage level.

  • Medicare Part D 2009 Data Spotlight: Specialty Tiers

    Issue Brief

    Most Medicare Part D prescription drug plans use tiers with different cost-sharing amounts for generic, preferred, and non-preferred drugs, and also include an additional “specialty” tier for very high cost and unique drugs.